These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
462 related articles for article (PubMed ID: 10761530)
21. Comparison of autografting using mobilized peripheral blood stem cells with and without granulocyte colony-stimulating factor in malignant lymphomas. Brice P; Divine M; Marolleau JP; Haioun C; Dalcortivo L; Sitthy X; Beaujean F; Norol F; Benbunan M; Reyes F Bone Marrow Transplant; 1994 Jul; 14(1):51-5. PubMed ID: 7524907 [TBL] [Abstract][Full Text] [Related]
22. [Low-dose granulocyte colony-stimulating factor combined with granulocyte-macrophage colony-stimulating factor for mobilizing peripheral CD34+ hematopoietic progenitor cells]. Meng FY; Xu B; Sun J; Yang Y; Niu JN Di Yi Jun Yi Da Xue Xue Bao; 2004 Sep; 24(9):1051-2. PubMed ID: 15447861 [TBL] [Abstract][Full Text] [Related]
23. The use of G-CSF during first line chemotherapy adversely affects the yield of PBSC mobilization in non-Hodgkin's lymphoma patients. Damiani D; Grimaz S; Sperotto A; Geromin A; Skert C; Cerno M; Rinaldi C; Fanin R Adv Clin Path; 2002 Jan; 6(1):11-6. PubMed ID: 17582943 [TBL] [Abstract][Full Text] [Related]
24. Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma. Kim S; Kim HJ; Park JS; Lee J; Chi HS; Park CJ; Huh J; Suh C Ann Hematol; 2005 Oct; 84(11):742-7. PubMed ID: 16132903 [TBL] [Abstract][Full Text] [Related]
25. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF]. Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou SY; Zhou AP; Zhang CG; Ai B Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058 [TBL] [Abstract][Full Text] [Related]
26. Peripheral blood stem cell (PBSC) mobilization with chemotherapy followed by sequential IL-3 and G-CSF administration in extensively pretreated patients. Kolbe K; Peschel C; Rupilius B; Després D; Burger K; Sklenar I; Färber L; Huber C; Derigs HG Bone Marrow Transplant; 1997 Dec; 20(12):1027-32. PubMed ID: 9466274 [TBL] [Abstract][Full Text] [Related]
27. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609 [TBL] [Abstract][Full Text] [Related]
28. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253 [TBL] [Abstract][Full Text] [Related]
29. Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease. McQuaker I; Haynes A; Stainer C; Byrne J; Russell N Bone Marrow Transplant; 1999 Oct; 24(7):715-22. PubMed ID: 10516673 [TBL] [Abstract][Full Text] [Related]
30. The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients. Lefrère F; Zohar S; Ghez D; Delarue R; Audat F; Suarez F; Hermine O; Damaj G; Maillard N; Ribeil JA; Azagury M; Misbahi R; Jondeau K; Cavazzana-Calvo M; Dal Cortivo L; Varet B Bone Marrow Transplant; 2006 Apr; 37(8):725-9. PubMed ID: 16518433 [TBL] [Abstract][Full Text] [Related]
31. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF. Callera F; Cavenaghi L; de Melo CM Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728 [TBL] [Abstract][Full Text] [Related]
32. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial. Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838 [TBL] [Abstract][Full Text] [Related]
33. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Lonial S; Hicks M; Rosenthal H; Langston A; Redei I; Torre C; Duenzl M; Feinstein B; Cherry J; Waller EK Biol Blood Marrow Transplant; 2004 Dec; 10(12):848-57. PubMed ID: 15570253 [TBL] [Abstract][Full Text] [Related]